BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed a definitive agreement with the Mayo Clinic in Rochester, Minnesota to conduct its Phase II clinical trial of NurOwn TM in amyotrophic lateral sclerosis (ALS), pending FDA approval. In addition, Mayo's Human Cell Therapy Laboratory will manufacture the NurOwn cells for their clinical trial participants. The other two sites slated for the multi-center trial are the University of Massachusetts Memorial Hospital and Massachusetts General Hospital.
"We are delighted to be progressing further with our preparations for the trial and honored to be collaborating with Professor Anthony Windebank and the Mayo Clinic," said Chaim Lebovits, President of BrainStorm. Mayo Clinic is one of the largest stem cell clinical trial centers worldwide, with 27 trials currently in Phase I.
"BrainStorm's mesenchymal stem cell-based approach is very compatible with some of the research conducted in our center," commented Anthony Windebank, M.D., Professor of Neurology and Principal Investigator of the study. "This trial is a logical next step in developing novel treatments for ALS which is a terrible disease with no effective treatment for our patients and their families."
About BrainStorm Cell Therapeutics, Inc.
BrainStorm
Cell Therapeutics Inc. is a biotechnology company engaged in the
development of first-of-its-kind adult stem cell therapies derived from
autologous bone marrow cells for the treatment of neurodegenerative
diseases. The Company holds the rights to develop and commercialize its
NurOwn technology through an exclusive, worldwide licensing agreement
with Ramot, the technology transfer company of Tel Aviv University. For
more information, visit the company's website at www.brainstorm-cell.com.
Safe Harbor Statement
Statements in this
announcement other than historical data and information constitute
"forward-looking statements" and involve risks and uncertainties that
could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking
statements. Terms and phrases such as "may", "should", "would", "could",
"will", "expect", "likely", "believe", "plan", "estimate", "predict",
"potential", and similar terms and phrases are intended to
identify these forward-looking statements. The potential risks
and uncertainties include, without limitation, risks associated with
BrainStorm's limited operating history, history of losses; minimal
working capital, dependence on its license to Ramot's technology;
ability to adequately protect the technology; dependence on key
executives and on its scientific consultants; ability to obtain required
regulatory approvals; and other factors detailed in BrainStorm's annual
report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov.
These factors should be considered carefully, and readers should not
place undue reliance on BrainStorm's forward-looking statements. The
forward-looking statements contained in this press release are based on
the beliefs, expectations and opinions of management as of the date of
this press release. We do not assume any obligation to update
forward-looking statements to reflect actual results or assumptions if
circumstances or management's beliefs, expectations or opinions should
change, unless otherwise required by law. Although we believe that the
expectations reflected in the forward-looking statements are reasonable,
we cannot guarantee future results, levels of activity, performance or
achievements.
BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI)
Mr. Chaim
Lebovits, President
+972-3-9236384
info@brainstorm-cell.com
www.brainstorm-cell.com